Entrada Therapeutics filings document a clinical-stage biopharmaceutical issuer developing genetic medicines that engage intracellular targets. Recent Form 8-K reports furnish quarterly and annual financial results, cash and marketable-securities updates, and corporate updates related to its Duchenne muscular dystrophy franchise, ocular disease pipeline and partnered VX-670 program for myotonic dystrophy type 1.
Proxy materials describe annual meeting matters, including director elections, auditor ratification and amendments to the company’s stock option and employee stock purchase plans. The filings also identify TRDA common stock listed on The Nasdaq Global Market, emerging growth company status, Regulation FD disclosures and governance matters tied to equity compensation and stockholder voting.
Entrada Therapeutics, Inc. (TRDA) had indirect shareholders affiliated with the MPM BioVentures funds report open-market sales of its common stock. Across three transactions on August 27, 28 and 31, 2026, entities including MPM BioVentures 2014, L.P., MPM BioVentures 2018, L.P. and related funds sold a total of 86,914 shares at weighted average prices ranging from about $6.76 to $7.37 per share. After the August 31 transaction, shares were held among these entities as follows: 1,921,425 by BV 2014, 128,155 by BV 2014(B), 66,136 by AM BV2014, 1,971,989 by BV 2018, 104,809 by BV 2018(B) and 38,920 by AM BV2018, and each reporting person disclaims beneficial ownership except to the extent of its pecuniary interest.
Entrada Therapeutics, Inc. (TRDA) reported that investment funds affiliated with MPM BioVentures, as ten percent owners, sold a total of 62,714 shares of Common Stock in open‑market or private transactions on August 24–26, 2026 at weighted‑average prices described in price ranges between approximately $6.97 and $7.64 per share.
The sales were executed indirectly through multiple MPM BioVentures partnerships and LLCs, and each reporting person disclaims beneficial ownership except to the extent of its or his pecuniary interest. After the August 26, 2026 transactions, MPM BioVentures entities collectively continued to hold substantial TRDA positions as detailed in the footnotes.
Entrada Therapeutics, Inc. (TRDA) had affiliated investment entities associated with MPM BioVentures, including MPM BioVentures 2018, L.P., a ten percent owner, report open-market sales of an aggregate 62,714 shares of common stock over three days at weighted average prices around the reported per-share figures. The sales were made indirectly through several MPM BioVentures and related LLC and limited partnership vehicles, and each reporting person disclaims beneficial ownership except to the extent of its pecuniary interest.
Entrada Therapeutics, Inc. is the subject of an amended Schedule 13G filing by TCG Crossover Fund I, L.P., TCG Crossover GP I, LLC and Chen Yu regarding their holdings of Entrada common stock. The reporting persons collectively report beneficial ownership of 1,060,230 shares of common stock, representing 2.7% of the class, based on 38,820,616 shares outstanding as of April 30, 2026. The shares are held of record by TCG Crossover Fund I, L.P., with voting and dispositive power shared among the reporting entities, each of which disclaims beneficial ownership except to the extent of its or his pecuniary interest.
Entrada Therapeutics director Kush Parmar reported indirect sales of 155,255 shares of Common Stock of Entrada Therapeutics, Inc., executed by investment entities he helps manage. The shares were sold on August 6, 7, and 10, 2026 at weighted average prices in the $6.80–$7.20 per-share range. After these transactions, an affiliated fund, 5AM Opportunities I, L.P., is reported as indirectly holding 1,093,313 shares, with Parmar disclaiming beneficial ownership beyond his pecuniary interest.
Entrada Therapeutics, Inc. reported that investment funds affiliated with 5AM Ventures, a 10% stockholder, sold a total of 62,811 shares of Common Stock in open-market transactions on August 6–7, 2026, at weighted average prices of $7.00 and $6.85 per share. The August 6 sale of 10,494 shares occurred within a price range of $6.90–$7.11, and the August 7 sale of 52,317 shares occurred within a price range of $6.80–$7.01. Following these transactions, an affiliated fund, 5AM Opportunities I, L.P., is reported as holding 1,093,313 shares of Entrada Therapeutics Common Stock indirectly. Certain managing members of the general partners may be deemed to share voting and investment power over these fund-held shares, while disclaiming beneficial ownership except to the extent of their pecuniary interest.
Entrada Therapeutics, Inc. filed an amended Form 144 indicating a planned resale of 331,156 shares of common stock. The shares were originally acquired on October 12, 2016 for cash in connection with a venture financing investment. The common stock is listed on Nasdaq.
Entrada Therapeutics filed its quarterly report for the period ended June 30, 2026, reporting a Q2 2026 net loss of $42.8 million and a six‑month net loss of $82.5 million. Collaboration revenue was $0.9 million in Q2 and $1.8 million year‑to‑date, down from the prior year after earlier completion of major Vertex-related research milestones.
Research and development expenses were $35.4 million in Q2 and $68.4 million for six months, slightly below 2025, while general and administrative expenses were $10.5 million in Q2. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $223.0 million; the company believes this will fund operations into the third quarter of 2027.
Clinically, Entrada highlighted Cohort 1 data from its ELEVATE‑44‑201 trial of ENTR‑601‑44 in Duchenne muscular dystrophy, showing a mean dystrophin increase to 6.36% (up 2.36 percentage points from baseline) and statistically significant improvements in Time to Rise and Time to Rise velocity versus placebo at a 6 mg/kg dose. Multiple additional DMD and ocular programs, and the VX‑670 DM1 collaboration with Vertex, continue to advance with several data readouts expected between late 2026 and early 2027.
Entrada Therapeutics reported second quarter 2026 results and outlined multiple upcoming clinical milestones across its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) programs. Cash, cash equivalents and marketable securities were $223.0 million as of June 30, 2026, versus $295.7 million as of December 31, 2025, and the company expects this to fund operations into the third quarter of 2027.
For Q2 2026, collaboration revenue was $0.9 million, R&D expenses were $35.4 million, G&A expenses were $10.5 million, and net loss was $42.8 million, or $1.01 per share. The company highlighted progress in its ELEVATE-44-201, ELEVATE-45-201 and ELEVATE-50-201 DMD studies, plans to advance ENTR-601-51, and ongoing development of VX-670 with Vertex, with multiple data readouts expected between the second half of 2026 and the first half of 2027.
5AM Ventures V, L.P., a ten percent shareholder of Entrada Therapeutics, reported open-market or private sales totaling 116,474 shares of common stock on July 30–31, 2026, at prices including a weighted average of $6.93 per share (with trades from $6.75 to $6.95) and $6.85 per share. Separately, 1,093,313 shares are reported as indirectly held as of July 30, 2026 by 5AM Opportunities I, L.P., with affiliated entities and individuals disclaiming beneficial ownership except to the extent of their pecuniary interests.